Betta Pharmaceuticals' performance last year suggests unreso...

Betta Pharmaceuticals' performance last year suggests unresolved challenges, worse than the annualized loss of 0.9% over the last half decade. This long-term share price weakness may be a bad sign, but contrarian investors might see it as a potential turnaround opportunity.